13 Best Get Rich Fast Stocks to Buy Right Now

Page 5 of 12

8. Cerus Corporation (NASDAQ:CERS)

Upside Potential as of December 24, 2025: 142.72%

Number of Hedge Fund Holders: 15

Share Price as of December 24, 2025: $2.06

On December 23, TheFly reported that TD Cowen views Cerus Corporation (NASDAQ:CERS)’s Intercept Fibrinogen Complex franchise as an “underappreciated” growth engine in the long haul. The firm believes the newly announced BCA partnership will significantly enhance its adoption, scalability, and profitability across the U.S. blood center space.

With that said, the financial services firm remains confident in the sustainability of the company’s double-digit revenue growth trajectory and finds the current valuation appealing. TD Cowen maintains a ‘Buy’ rating on Cerus Corporation (NASDAQ:CERS) with a price target of $5. This reflects a potential upside of 143%.

Earlier on December 10, Cerus Corporation (NASDAQ:CERS) announced that it had signed a purchasing agreement with Blood Centers of America (BCA), a leading blood supply cooperative in the United States. The agreement incorporates the company’s complete INTERCEPT product offering, including the pathogen reduction technology.

With an aim to enhance awareness and adoption of pathogen reduction technologies, the venture is anticipated to “provide access to pathogen-reduced platelets for new customers.” As stated by the COO of Cerus Corporation (NASDAQ:CERS), Vivek Jayaraman,

“I believe this agreement has the potential to be quite positive for BCA, their blood center membership and Cerus.”

Cerus Corporation (NASDAQ:CERS) is a California-based biomedical products company specializing in the INTERCEPT Blood System. Incorporated in 1991, the company offers platelet and plasma systems through a direct sales force and distributors.

Page 5 of 12